{
 "name": "圓祥生技",
 "slug": "tw-6945",
 "aliases": [
  "圓祥生技股份有限公司",
  "APBio",
  "6945"
 ],
 "ticker": "6945",
 "industry": "生技醫療業",
 "website": "www.apbioinc.com",
 "summary": "圓祥生技（6945）是上櫃的生技醫療類股公司，2013 年成立，2026 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "圓祥生技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "APBio",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2026-06-05",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2013-05-27",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "陳志全",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "何正宏",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 975311600,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "www.apbioinc.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 0,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不符合本次白名單；回查官方115年09月營收申報，claim/value/unit/as_of保留，僅更正輸出複本source。核對列與原來源保存在research/basic_source_corrections.json。"
  },
  {
   "claim": "管線：IBI302",
   "value": "濕性年齡相關黃斑部病變｜關鍵第III期STAR研究達成主要終點｜中國",
   "unit": "",
   "as_of": "2026-03-24",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=4&spoke_time=153559&spoke_date=20260324&co_id=6945&TYPEK=otc",
   "note": "發言日期：115/03/24；主旨：本公司授權信達生物製藥（蘇州）有限公司IBI302 關鍵三期註冊臨床試驗(STAR研究)達成主要終點。NCT05972473；達成主要終點不等於已取得上市許可。"
  },
  {
   "claim": "管線：AP505（B1962）",
   "value": "實體腫瘤及大腸直腸癌｜第II期臨床｜中國",
   "unit": "",
   "as_of": "2026-05-14",
   "source": "https://www.apbioinc.com/Upload/202605/investor_2026051315284608.pdf",
   "note": "NCT06724263、NCT06838546；法說公開日依公司2026-05-14活動稿，https://www.apbioinc.com/investor7-15-0-0.htm"
  },
  {
   "claim": "管線：AP203",
   "value": "局部晚期或轉移性實體腫瘤｜登錄為第I／II期試驗、收案中｜台灣",
   "unit": "",
   "as_of": "2025-03-26",
   "source": "https://clinicaltrials.gov/study/NCT05473156",
   "note": "NCT05473156；抽查發現登錄designModule.phases同列PHASE1及PHASE2，已由「第I期」修正。登錄最後更新2025-03-26；公司2026年5月法說仍列一期，未推定已進入二期。"
  },
  {
   "claim": "管線：AP402",
   "value": "HER2陽性實體腫瘤｜第I期已完成首例收案｜澳洲",
   "unit": "",
   "as_of": "2025-04-22",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=3&spoke_time=153440&spoke_date=20250422&co_id=6945&TYPEK=otc",
   "note": "發言日期：114/04/22；主旨：代子公司APBIO PTY LTD公告研發中雙特異性抗體 抗癌新藥AP402於澳洲治療HER2陽性實體腫瘤第一期 臨床試驗完成第一例受試者收案。NCT06669975；公司發言日不等同主管機關核准日。"
  },
  {
   "claim": "管線：AP601",
   "value": "實體腫瘤｜第I期已完成首例收案｜澳洲",
   "unit": "",
   "as_of": "2026-02-24",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=2&spoke_time=165913&spoke_date=20260224&co_id=6945&TYPEK=otc",
   "note": "發言日期：115/02/24；主旨：代子公司APBIO PTY LTD公告研發中雙特異性抗體抗癌新 藥AP601，於澳洲治療實體腫瘤第一期臨床試驗完成第一例受 試者收案。NCT07165067；首例用藥年月與法說表可能不同，本筆依MOPS第一例收案公告，不混作同事件日期。"
  },
  {
   "claim": "授權合作：AP505（合作補充協議）",
   "value": "Tasly Pharmaceutical Group Co., Ltd.（天士力）｜中國以外授權及全球商務發展收益安排｜2026-03-30",
   "unit": "",
   "as_of": "2026-03-30",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=2&spoke_time=150615&spoke_date=20260330&co_id=6945&TYPEK=otc",
   "note": "發言日期：115/03/30；主旨：公告本公司與天士力醫藥集團股份有限公司簽訂AP505 合作補充協議。原2019年中國區授權之增補，非新增中國以外獨家權利授予天士力；收益分成比例未公開。"
  },
  {
   "claim": "催化劑：AP402",
   "value": "完成第I期收案目標｜2026Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-14",
   "source": "https://www.apbioinc.com/Upload/202605/investor_2026051315284608.pdf",
   "note": "採較窄之法說第7頁「完成收案」；第31頁另寫「臨床一期完成」，兩者範圍不同，不把完成收案當成全部臨床試驗完成。"
  },
  {
   "claim": "催化劑：AP601",
   "value": "完成第I期收案目標｜2027上半年（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-14",
   "source": "https://www.apbioinc.com/Upload/202605/investor_2026051315284608.pdf"
  },
  {
   "claim": "催化劑：IBI302（DME）",
   "value": "糖尿病黃斑部水腫試驗主要完成｜2026-12-31（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-27",
   "source": "https://clinicaltrials.gov/study/NCT06908876",
   "note": "NCT06908876；primaryCompletionDateStruct.type=ESTIMATED，為試驗登錄預估，不是主管機關承諾或實際完成。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6945.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}